

RD General Agenda Topics – December 15, 2020

New Active Ingredients (include original PRIA date)

- **Tetraniliprole** – PD signed. PRIA date 12/24/20 (Original PRIA date 3/27/19) (IVB3). FRN in RD-IO coming to OPP-IO soon. Significant comments on the PD (over 7000) including significant issues raised by pollinator stewardship council.
- **Broflanilide** – **Team addressing public comments**. PRIA date negotiated to **1/15/20** (Original PRIA date 12/19/19) (IVB1). **Planning to make it in Jan.**
- **Fluindapyr** – **Minor comments back to the team**. Company withdrew foliar use on soybeans. PRIA Date 12/31/20 (Original PRIA date 5/29/20) (FB)
- **Trifludimoxazin** – PD signed. PRIA date 12/18/20 (Original PRIA date 10/16/2020)
- **Picarbutrazox** – RD providing comments to the team. **PD coming IO soon**. PRIA date 12/31/2020 (Original PRIA date 10/16/2020)

Other Chemical Actions

- Dicamba (Dan K)
 - **IL – interested in supplemental labeling to address more restrictions (June 20, 85 degree cutoff); MN is going with federal restrictions**
- Antibiotics – developing comparison schedule (Cynthia)
 - **Streptomycin – developing RTC/FD**
 - Oxytet – cherry; Dec; public process
 - Consultation with partners – Kasugamycin (almond, peach, apricot)
- **Aldicarb** – (Marion)
 - Working with OGC to negotiate production cap;
 - **Bee risk issues**
 - **Talking to FL**
- Cyclaniliprole/flonicamid – RD IO review; first residential use; public process; IVB1/IVB2 coordinating on proposed bee language; coming to OPP IO soon
- Seresto – pet collar with high rate of incidents (death and neuro); planning a briefing

Other Actions - AA-Level/OD/High Visibility Items

- COVID-19 Activities – Sect 18s –
 - SW2 – OK, AR has submitted

Ex. 5 Deliberative Process (DP)

- Grignard/VT
- OIG Audits

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

- Formulator's exemption (Bo)
 - new J. Jones memo (sent to the OPP-IO)
 - Syngenta – request to cancel Atticus registrations
 - OGC is proposing that we write up something short that explains that, during the time of approval, RD was following all of our current policies.

Ex. 5 Attorney Client (AC)

- **Final Efficacy Test Guidelines** (Fire Ants, Pests of Pets): briefing OMB 12/17 re: significance determination, guidelines coming to OPP IO for review/clearance in Dec (the team worked with Anna L. during guideline development). **Do you want a briefing on the package contents?**
- ISB – FEP issues; follow up meeting;
- Spartan Mosquito – one pager with OCSPP/Administrator; **letter drafted; in review by BPPD IO**
- PFAS – 8 legacy inerts removed from Inert Finder
- AAPCO Label Project – VA, IN, ME etc. plus EPA
- Gold Seals –OMB review concluded and OPP update issued; team working on slides for webinar to CLA/RISE workgroup (date TBD)– (Marion)
- FLS/FLAG: working with OCSPP IO and Ramona Trovato et al. on next Transition Mgt session (via FLS Coffee and Conversations)

Speaking Engagements –

- Gold Seal Updates for CLA/RISE Workgroup (Catherine Aubee, Shanta Adeeb, Marion Johnson, ITRMD participant), (date TBD)

Ex. 6 Personal Privacy (PP)